In The News

A Fixed Ratio Combination of Insulin Degludec and Liraglutide (IDegLira) Reduces Glycemic Fluctuation and Brings More Patients With Type 2 Diabetes Within Blood Glucose Target Ranges

March 2017. This analysis assessed glycemic fluctuations and day-to-day blood glucose variability in patients treated with IDegLira compared with either insulin degludec (IDeg) or liraglutide alone. Investigators analyzed data from 2 randomized trials in patients with type 2 diabetes (T2D); in particular, 9-point self-monitored blood glucose (SMBG) profiles and continuous glucose monitoring (CGM) data from a patient subset.

Diabetic Retinopathy: A Position Statement by the American Diabetes Association

March 2017. The American Diabetes Association has updated its Position Statement on diabetic retinopathy for the first time since 2002. The update focuses on improvements in diabetic retinopathy assessment and treatment options, including optical coherence tomography to assess retinal thickness and intraretinal pathology and wide-field fundus photography to reveal clinically silent microvascular lesions. Improvements in medications and devices for systemic diabetes therapy are also discussed.

3 Years of Liraglutide vs Placebo for Type 2 Diabetes Risk Reduction and Weight Management in Individuals With Prediabetes

February 22, 2017. This randomized, controlled, double-blind trial evaluated the proportion of patients with prediabetes and obesity/overweight treated with liraglutide 3.0 mg vs placebo over a 3-year period to determine time to diabetes onset. Patients (N=2,254) from 191 clinical research sites were randomized 2:1; all were assigned to caloric restriction and increased physical activity. Fifty percent of patients completed the full study; patients who withdrew were not followed after discontinuation.

Safety and Efficacy of IDegLira Titrated Once Weekly vs Twice Weekly in Patients With Type 2 Diabetes Uncontrolled on Oral Antidiabetic Drugs

March 3, 2017. This open-label trial evaluated the impact of IDegLira (combined insulin degludec and the glucagon-like peptide-1 inhibitor liraglutide) once or twice weekly in insulin-naïve adults with type 2 diabetes inadequately controlled on metformin ± pioglitazone. A total of 420 patients were randomized to this 32-week non-inferiority trial. IDegLira was titrated either once or twice weekly based on mean pre-breakfast plasma glucose readings. With once-weekly titration, mean A1C decreased from 8.2% to 6.1%; reductions for twice-weekly titration were from 8.1% to 6.0%.

Diabetic Retinopathy: A Position Statement by the American Diabetes Association

March 2017. The American Diabetes Association (ADA) has released a position statement on diabetic retinopathy. This is an update of the ADA’s 2002 position statement.

FDA Approves Combined Dapagliflozin/Saxagliptin for Adults With Type 2 Diabetes

February 28, 2017. The US Food and Drug Administration has approved a once-daily formulation of dapagliflozin 10 mg and saxagliptin 5 mg (trade name Qtern). Qtern provides dual antihyperglycemic therapy to patients with type 2 diabetes by combining a sodium-glucose cotransporter-2 inhibitor and dipeptidyl peptidase-4 inhibitor in a single daily tablet. Click here for full article

FDA Approves Label Update for Dulaglutide to Include Use in Combination With Basal Insulin

February 8, 2017. The US Food and Drug Administration has approved a label update for the glucagon-like-1 (GLP-1) receptor agonist dulaglutide. Dulaglutide is now approved for use in combination with basal insulin in adults with type 2 diabetes. This update makes dulaglutide the first GLP-1 receptor agonist indicated for combination use with mealtime insulin or basal insulin.

Chronic Liraglutide Therapy Induces an Enhanced Endogenous Glucagon-like Peptide-1 Secretory Response in Early Type 2 Diabetes

January 2017. This study evaluated the impact of chronic liraglutide therapy on endogenous glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Fifty-one patients with type 2 diabetes (mean duration, 2.6 years, +/- 1.9 years) were randomized for 48 weeks to subcutaneous liraglutide or placebo. Patients received an oral glucose tolerance test (OGTT) every 12 weeks, with GLP-1 and GIP area under the curve (AUC) measured at 0, 30, 60, 90, and 120 minutes. No between-group differences were observed for AUC GIP.

Use of Incretin Agents and Risk of Acute and Chronic Pancreatitis: A Population-Based Cohort Study

January 2017. This population-based matched cohort study was conducted in a United Kingdom population to assess pancreatitis risk in patients with type 2 diabetes receiving incretin therapy (either dipeptidyl peptidase-4 inhibitors or glucagon-like peptide-1 receptor agonists). Adult patients (N=182,428) using ≥1 diabetes medication (excluding insulin) were matched to controls without diabetes.

Insulin-Requiring Versus Noninsulin-Requiring Diabetes and Thromboembolic Risk in Patients With Atrial Fibrillation

January 31, 2017. This prospective, real-world, multicenter study evaluated the impact of insulin vs no insulin therapy on thromboembolic risk in patients with diabetes and atrial fibrillation (AF) being treated with anticoagulation therapy. Rates of stroke and systemic embolism were compared over 1 year based on patient diabetes and insulin use status.